Takeda launches Adynovate to advance prophylaxis treatment for haemophilia patients in India

Takeda Pharma has expanded its innovative rare diseases portfolio in India with the launch of Adynovate, an innovative extended half-life recombinant Factor VIII (rFVIII) treatment, using established technology (controlled PEGylation), for haemophilia A patients, a company statement said.

It also said that Adynovate, in combination with MYPKFIT, the first and only FDA-approved application, offers personalised and interactive prophylaxis treatment option that enables both healthcare professionals and patients in real-time monitoring of factor VIII levels from the comfort of their homes on phone thereby adapting their activity decisions accordingly and help improve their quality of life. Alerts are sent to patients on prophylaxis when their estimated factor VIII levels are low, and reminds them when their infusions are due, thereby providing excellent prophylactic coverage.

Administered in three steps with BAXJECT III system, Adynovate eliminates the need to disinfect the vial, as vials are already assembled in the system housing. It can be stored at room temperature not to exceed 30°C (86°F) for a period of up to three months not to exceed the expiration date thereby easing the handling and storing process. As a global leader in pharma, Takeda Pharma has been focussed on driving comprehensive research to support the development of effective and innovative treatments in the company’s chosen therapy areas. Takeda India is part of Takeda Pharma’s group of companies headquartered in Japan. The company focusses on haematology, genetic diseases, immunology and gastrointestinal portfolios in the country, the statement concluded.